Crescent Biopharma, Inc. (CBIO) Earnings
Crescent Biopharma, Inc. is expected to report next earnings on July 30, 2026 (in NaN days), with a consensus EPS estimate of $-0.78. CBIO has beaten EPS estimates in 7 of its last 12 reported quarters (average surprise -17.8% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Apr 29, 2026 | $-0.85 | $-0.70 | +17.6% | $1M | +180.0% |
| Nov 6, 2025 | $-1.01 | $-1.27 | -25.7% | — | — |
| Jul 31, 2025 | $-2.69 | $-4.93 | -83.3% | — | — |
| May 14, 2025 | $-0.05 | $-0.04 | +20.0% | — | — |
| Feb 13, 2025 | $-0.16 | $-0.11 | +31.3% | $54086 | — |
| Aug 8, 2024 | $-0.17 | $-0.16 | +5.9% | — | — |
| May 9, 2024 | $-0.16 | $-0.17 | -6.3% | — | — |
| Nov 3, 2023 | $-0.14 | $-0.14 | +0.0% | — | — |
| Aug 2, 2023 | $-0.18 | $-0.13 | +27.8% | — | — |
| May 3, 2023 | $-0.17 | $-0.17 | +0.0% | — | — |
| Nov 9, 2022 | $-0.26 | $-0.16 | +38.5% | — | — |
| Aug 3, 2022 | $-0.29 | $-0.25 | +13.8% | $75000 | — |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2024 · May 6, 2024
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
- Announced top line results from the pivotal Phase III study of uproleselan vs placebo in combination with MEC or FAI for relapsed/refractory acute myeloid leukemia; study did not achieve statistical significance in overall survival in intent-to-treat population. - Adverse events consistent with known side effects of chemotherapies used in the study. - Evaluating full data set with medical, statistical, and regulatory experts and plan to share further updates; intend to present comprehensive data analysis at a medical meeting and discuss with FDA due to significant unmet patient need. - Thanked investigators, trial sites, patients, families, and GlycoMimetics team. - National Cancer Institute is sponsoring an ongoing Phase II/III trial evaluating uproleselan in newly diagnosed older patients with AML fit for intensive chemotherapy; look forward to sharing results when available. - Revising budget and updating plans for uproleselan in the coming weeks.
Guidance
- Plan to report back to investors regarding a revised budget in the coming weeks. - Will share updated plans for uproleselan as soon as reasonably possible. - Will have additional conversations with the NCI team regarding their trial in light of the data from the Phase III study.
Segment performance
No specific product segment financial performance discussed as the transcript focuses on the uproleselan Phase III study.
Risks & headwinds
- Forward-looking statements involve assumptions, risks, and uncertainties; refer to GlycoMimetics' filings with the SEC for risk factors that could affect the company.
Analyst Q&A
Q: Thoughts on why the study took longer to read out than initially expected and why the control group median survival was unprecedented?
A: Trial took longer because patients lived longer than anticipated; control arm median overall survival of over 1 year is one of the highest in relapsed/refractory setting; conducting full analysis to understand insights and share at a medical conference.
Q: Impact on NCI study and Apollomics study in China?
A: Won't comment on Apollomics' trials in China; regarding NCI trial, will have additional conversations with NCI team, noting it's a different line of therapy with different backbone therapy and endpoint.
Q: Thoughts on strategy going forward with study 1687?
A: 1687 is a good asset, advanced through IND and Phase Ia; will revise budget, conserve cash, focus on understanding 301 and working closely with regulatory, clinical, and statistical partners.
Q: Sub-populations where uproleselan could be more effective?
A: Study not powered for subgroups, but design includes stratification factors; will conduct comprehensive review of full data set to understand sub-group effectiveness.
Q: Thoughts on FDA support for potential filing in a limited population?
A: Had good conversations with FDA during trial development; will deepen understanding and engage with FDA to see if there's a path forward, but too early to speculate.
Q: MRD-positive/-negative patients, transplant rates, and MRD-negativity?
A: Data on MRD-negativity, transplant rates, etc., is being looked at by the team; will compile insights and have conversations with regulatory agencies like the FDA.